The global Primary Sclerosing Cholangitis Market is estimated to be valued at US$ 1.98 Mn in 2023 and is expected to exhibit a CAGR of 7.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:

Primary sclerosing cholangitis (PSC) is a chronic inflammatory disease associated with autoimmune disorders involving narrowing and scarring of the bile ducts within and outside of the liver. Symptoms include jaundice, fatigue, and itchy skin. Ursodeoxycholic acid medications help reduce bile acids and slow disease progression.

Market key trends:

One of the main trends in the primary sclerosing cholangitis market is the rise of biologic therapies. Biologics target specific components of the immune system involved in PSC pathogenesis. Monoclonal antibodies that modulate interleukin 12/23 activity are emerging as promising candidates and in late stage clinical trials. Increasing research focus on therapies aimed at blocking inflammatory pathways makes biologics one of the fastest growing treatment segments.

Segment Analysis:

Primary Sclerosing Cholangitis market Growth  is segmented on the basis of drug type, distribution channel, and geography. Based on drug type, the market is segmented into ursodeoxycholic acid, obeticholic acid, and other drug types. Ursodeoxycholic acid dominates the global primary sclerosing cholangitis market as it is the first line of treatment and is comparatively more affordable than other drugs.

Key Takeaways

The global primary sclerosing cholangitis market is expected to witness high growth, exhibiting CAGR of 7.6% over the forecast period, due to increasing prevalence of inflammatory bowel diseases and growing awareness regarding early diagnosis of primary sclerosing cholangitis.

The North America dominates the global primary sclerosing cholangitis market owing to the presence of major market players and higher adoption of novel therapies in the region. Europe is expected to be the second largest market due to increasing research funding for rare disease treatment. Asia Pacific exhibits the highest growth rate over the forecast period due to rising healthcare expenditure and growing patient population.

Key players operating in the primary sclerosing cholangitis market are Acorda Therapeutics, Inc., Gilead Sciences, Inc., NGM Biopharmaceuticals, Inc., Intercept Pharmaceuticals, Inc., Dr. Falk Pharma GmbH, Allergan Plc., Shire Plc., Durect Corporation, Conatus Pharmaceuticals, Inc., Sirnaomics, Inc., and Shenzhen HighTide Biopharmaceutical Ltd. The key players are majorly focused on developing advanced therapeutic options. For instance, in November 2021, Intercept Pharmaceuticals, Inc. received Fast Track designation from the U.S. FDA for obeticholic acid for the treatment of liver fibrosis due to primary sclerosing cholangitis.

Read Our More Blogs : https://www.rapidwebwire.com/primary-sclerosing-cholangitis-market-analysis-outlook-trends-2023-2030/